Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Emergent Biosolutions, Inc. (EBS) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Emergent Biosolutions, Inc. (EBS) lobbying for?
Summary of the lobbying data:
Emergent Biosolutions, Inc. submitted 10 recent lobbying contracts with various lobbying firms such as Navigators Global Llc, Capitol Counsel Llc, and Forbes-Tate. They lobbied on general issues such as Homeland Security, Disaster Planning/Emergencies, Defense, Health Issues, and Budget/Appropriations. Specific issues include the stockpiling of medical countermeasures (MCM) for the U.S. Government, Health and Human Services, State Opioid Response (SOR) Grants, and Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. They also lobbied on issues related to the development, distribution, and access to coronavirus vaccines, naloxone access and awareness, and opioid prescribing guidelines. Emergent Biosolutions, Inc. lobbied government agencies such as the Office of Natl Drug Control Policy, the Centers For Disease Control & Prevention, the Department of Health & Human Services, and the Substance Abuse & Mental Health Services Administration.
One could infer that Emergent Biosolutions, Inc. is lobbying on these issues to have a say in the policies affecting their business operations. As a company specializing in biopharmaceuticals, their lobbying efforts could be aimed at influencing government decisions regarding healthcare, funding of the Strategic National Stockpile, and acquisition and stockpiling of medical countermeasures. They could also be lobbying for funding for substance abuse and mental health programs as well as COVID-19 vaccine development and distribution. Lobbied government agencies such as the Office of Natl Drug Control Policy, Centers for Disease Control & Prevention and Department of Health & Human Services are crucial agencies shaping regulations for public health products, possibly explaining why they lobbied them.
